Dendritic cell fusion vaccines for cancer immunotherapy

Bibliography

• BOON T, VAN DER BRUGGEN P: Human tumor antigens recognized by T lymphocytes. J. Exp. Med. (1996) 183(3):725–729.
   PubMed Web of Science ®Google Scholar
• KAWAKAMI Y, ELIYAHU S, DELGADO CH et al.: Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA (1994) 91(14):6458–6462.
   PubMed Web of Science ®Google Scholar
• SPEISER DE, MIRANDA R, ZAKARIAN A et al.: Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J. Exp. Med. (1997) 186(5):645–653.
   PubMed Web of Science ®Google Scholar
• STEINMAN RM: The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol (1991) 9:271–296.
   PubMed Web of Science ®Google Scholar
• RIDG WAY D: The first 1000 dendritic cell vaccinees. Cancer Invest. (2003) 21(6):873–886.
   PubMed Web of Science ®Google Scholar
• BANCHEREAU J, BRIERE F, CAUX C et al.: Immunobiology of dendritic cells. Annu. Rev. Immunol (2000) 18:767–811.
   PubMed Web of Science ®Google Scholar
• AVIGAN D: Dendritic cells: development, function and potential use for cancer immunotherapy. Blood Rev. (1999) 13(1):51–64.
   PubMed Web of Science ®Google Scholar
• YOUNG P:(1, STEINMAN RM: The hematopoietic development of dendritic cells: a distinct pathway for myeloid differentiation. Stem Cells (1996) 14(4):376–387.
   PubMed Web of Science ®Google Scholar
• O'NEILL DW, ADAMS S, BHARDWAJ N: Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood (2004) 104(8):2235–2246.
   PubMed Web of Science ®Google Scholar
• YOUNG JW, KOULOVA L, SOERGEL SA et al.: The B7/BB1 antigen provides one of several costimulatory signals for the activation of CD4+ T lymphocytes by human blood dendritic cells in vitro. Clin. Invest. (1992) 90(1):229–237.
   Google Scholar
• INABA K, WITMER-PACK M, INABA M et al.: The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J. Exp. Med. (1994) 180(5):1849–1860.
   PubMed Web of Science ®Google Scholar
• ARDAVIN C, AMIGORENA S, REIS E SOUSA C: Dendritic cells: immunobiology and cancer immunotherapy. Immunity (2004) 20(1):17–23.
   PubMedGoogle Scholar
• SHIN T, KENNEDY G, GORSKI K et aL: Cooperative B7-1/2 (CD80/CD86) and B7-DC costimulation of CD4+ T cells independent of the PD-1 receptor. J. Exp. Med. (2003) 198(1):31–38.
   PubMed Web of Science ®Google Scholar
• PULENDRAN B, SMITH JL, CASPARY G et al.: Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc. NatL Acad. Sci. USA (1999) 96(3):1036–1041.
   PubMed Web of Science ®Google Scholar
• MOSEMAN EA, LIANG X, DAWSON AJ et al.: Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J. Immunol. (2004) 173(7):4433–4442.
   PubMed Web of Science ®Google Scholar
• SZABOLCS P, MOORE MA, YOUNG JW: Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-alpha. J. Immunol. (1995) 154(11):5851–5861.
   PubMed Web of Science ®Google Scholar
• ASKEW D, CHU RS, KRIEG AM, HARDING CV: CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms. J. Immunol. (2000) 165(12):6889–6895.
   PubMed Web of Science ®Google Scholar
• BRUNNER C, SEIDERER J, SCHLAMP A et al.: Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate- guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. J. Immunol. (2000) 165(11):6278–6286.
   PubMed Web of Science ®Google Scholar
• KELSALL BL, STUBER E, NEURATH M, STROBER W: Interleukin-12 production by dendritic cells. The role of CD4O-CD4OL interactions in Thl T-cell responses. Ann. IVY Acad. Sci. (1996)795:116–126.
   Google Scholar
• CELLA M, SCHEIDEGGER D, PALMER-LEHMANN K et aL: Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. (1996) 184(2):747–752.
   PubMed Web of Science ®Google Scholar
• TAKAYAMA T, MORELLI AE, ONAI N et aL: Mammalian and viral IL-10 enhance C-C chemokine receptor 5 but down-regulate C-C chemokine receptor 7 expression by myeloid dendritic cells: impact on chemotactic responses and in vivo homing ability. J. Immunol. (2001) 166(12):7136–7143.
   PubMed Web of Science ®Google Scholar
• TAKAYAMA T, NISHIOKA Y, LU L et aL: Retroviral delivery of viral interleukin-10 into myeloid dendritic cells markedly inhibits their allostimulatory activity and promotes the induction of T-cell hyporesponsiveness. Transplantation (1998) 66(12):1567–1574.
   PubMed Web of Science ®Google Scholar
• DE SMEDT T, VAN MECHELEN M, DE BECKER G et al.: Effect of interleukin-10 on dendritic cell maturation and function. Eur. J. Immunol. (1997) 27(5):1229–1235.
   Google Scholar
• STEINBRINK K, WOLFL M, JONULEIT H, KNOP J, ENK AH: Induction of tolerance by IL-10-treated dendritic cells./ Immunol. (1997) 159(10):4772–4780.
   PubMed Web of Science ®Google Scholar
• PAGLIA P, CHIODONI C, RODOLFO M, COLOMBO MP: Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. (1996) 183(1):317–322.
   PubMed Web of Science ®Google Scholar
• ASHLEY DM, FAIOLA B, NAIR S et aL: Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors./ Exp. Med. (1997) 186(7):1177–1182.
   Google Scholar
• NAIR SK, BOCZKOWSKI D, MORSE M et aL: Induction of primary carcinoembryonic antigen (CFA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat. BiotechnoL (1998) 16(0364–369.
   PubMed Web of Science ®Google Scholar
• MAYORDOMO JI, ZORINA T, STORKUS WJ et aL: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. (1995) 1(12):1297–1302.
   PubMed Web of Science ®Google Scholar
• CELLUZZI CM, MAYORDOMO JI, STORKUS WJ, LOTZE MT, FALO LD JR: Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med. (1996) 183(1):283–287.
   PubMed Web of Science ®Google Scholar
• ALBERT ML, SAUTER B, BHARDWAJ N: Dendritic cells acquire antigen from apoptotic cells and induce class I- restricted CTLs. Nature (1998) 392(6671):86–89.
   PubMed Web of Science ®Google Scholar
• HERR W, RANIERI E, OLSON W et al.: Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses. Blood (2000) 96(5):1857–1864.
   PubMed Web of Science ®Google Scholar
• SPISEK R, CHEVALLIER P, MORINEAU N et al.: Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin. Cancer Res. (2002) 62(10):2861–2868.
   PubMed Web of Science ®Google Scholar
• O'ROURKE MG, JOHNSON M, LANAGAN C et aL: Durable complete clinical responses in a Phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol. Immunother. (2003) 52(6):387–395.
   PubMed Web of Science ®Google Scholar
• DILLMAN R, SELVAN S, SCHILTZ P et al.: Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysis. Cancer Biother. Radiopharm. (2004) 19(5):658–665.
   PubMed Web of Science ®Google Scholar
• TANAKA F, HASHIMOTO W, ROBBINS PD, LOTZE MT, TAHARA H: Therapeutic and specific antitumor immunity induced by co-administration of immature dendritic cells and adenoviral vector expressing biologically active IL-18. Gene Ther. (2002) 9(21):1480–1486.
   PubMed Web of Science ®Google Scholar
• DRIESSENS G, HAMDANE M, COOLV, VELU T, BRUYNS C: Highly successful therapeutic vaccinations combining dendritic cells and tumor cells secreting granulocyte macrophage colony-stimulating factor. Cancer Res. (2004) 64(22):8435–8442.
   PubMed Web of Science ®Google Scholar
• SHACKLETON M, DAVIS ID, HOPKINS Wet al.: The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant F1t3 ligand. Cancer Immun. (2004) 4:9.
   Google Scholar
• O'KEEFFE M, HOCHREIN H, VREMEC D et aL: Effects of administration of progenipoietin 1, Flt-3 ligand, granulocyte colony-stimulating factor, and pegylated granulocyte-macrophage colony-stimulating factor on dendritic cell subsets in mice. Blood (2002) 99(6):2122–2130.
   PubMed Web of Science ®Google Scholar
• RINI BI, PAINTAL A. VOGELZANG NJ, GAJEWSKI TF, STADLER WM: Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity. J. Immunother. (2002) 25(3):269–277.
   PubMed Web of Science ®Google Scholar
• BANCHEREAU J, PALUCKA AK, DHODAPKAR M et aL: Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. (2001) 61(17):6451–6458.
   PubMed Web of Science ®Google Scholar
• NESTLE FO, ALIJAGIC S, GILLIET M et aL: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. (1998) 4(3):328–332.
   PubMed Web of Science ®Google Scholar
• YU JS, WHEELER CJ, ZELTZER PM et aL: Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. (2001) 61(3):842–847.
   PubMed Web of Science ®Google Scholar
• HSU FJ, BENIKE C, FAGNONI F et aL: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. (1996) 2(1):52–58.
   PubMed Web of Science ®Google Scholar
• PARKHURST MR, DEPAN C, RILEY JP, ROSENBERG SA, SHU S: Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules. J. ImmunoL (2003) 170(10):5317–5325.
   PubMed Web of Science ®Google Scholar
• GALEA-LAURI J, WELLS JW, DARLING D, HARRISON P, FARZANEH F: Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination. Cancer ImmunoL Immunother. (2004) 53(10:963–977.
   PubMedGoogle Scholar
• SHIMIZU K, KURIYAMA H, KJAERGAARD J et aL: Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. Immunother. (2004) 27(4):265–272.
   Web of Science ®Google Scholar
• GALEA-LAURI J, DARLING D, MUFTI G, HARRISON P, FARZANEH F: Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer ImmunoL Immunother. (2002) 51(6):299–310.
   PubMed Web of Science ®Google Scholar
• GODDARD RV, PRENTICE AG, COPPLESTONE JA, KAMINSKI ER: In vitro dendritic cell-induced T cell responses to B cell chronic lymphocytic leukaemia enhanced by IL-15 and dendritic cell-B-CLL electrofusion hybrids. Clin. Exp. ImmunoL (2003) 131(1):82–89.
   PubMed Web of Science ®Google Scholar
• GONG J, CHEN D, KASHIWABA M, KUFE D: Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med. (1997) 3(5):558–561.
   PubMed Web of Science ®Google Scholar
• GONG J, CHEN D, KASHIWABA M et al.: Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc. Natl. Acad. Sci. USA (1998) 95(11):6279–6283.
   PubMed Web of Science ®Google Scholar
• CELLUZZI CM, FALO LD JR: Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection./ ImmunoL (1998) 160(7):3081–3085.
   PubMed Web of Science ®Google Scholar
• HOMMA S, TODA G, GONG J, KUFE D, OHNO T: Preventive antitumor activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice. J. GastroenteroL (2001) 36(11):764–771.
   PubMed Web of Science ®Google Scholar
• LESPAGNARD L, METTENS P, VERHEYDEN AM et aL: Dendritic cells fused with mastocytoma cells elicit therapeutic antitumor immunity. Int. J. Cancer (1998) 76(2):250–258.
   PubMed Web of Science ®Google Scholar
• XIA J, TANAKA Y, KOIDO S et al.: Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/ tumor fusion cells. J. ImmunoL (2003) 170(4):1980–1986.
   PubMed Web of Science ®Google Scholar
• IINUMA T, HOMMA S, NODA T, KUFE D, OHNO T, TODA G: Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccine. J. Clin. Invest. (2004) 113(9):1307–1317.
   PubMed Web of Science ®Google Scholar
• IRIE M, HOMMA S, KOMITA H et al.: Inhibition of spontaneous development of liver tumors by inoculation with dendritic cells loaded with hepatocellular carcinoma cells in C3H/HeNCRJ mice. Int. J. Cancer (2004) 111(2):238–245.
   PubMed Web of Science ®Google Scholar
• CAO X, ZHANG W, WANG J et al.: Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells. Immunology (1999) 97(4):616–625.
   PubMed Web of Science ®Google Scholar
• GONG J, KOIDO S, CHEN D et aL: Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood (2002) 99(7):2512–2517.
   PubMed Web of Science ®Google Scholar
• AKASAKI Y, KIKUCHI T, HOMMA S et al.: Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model. J. Immunother. (2001) 24(2):106–113.
   Web of Science ®Google Scholar
• OGAWA F, IINUMA H, OKINAGA K: Dendritic cell vaccine therapy by immunization with fusion cells of interleukin-2 gene-transduced, spleen-derived dendritic cells and tumour cells. Scandj Immunol. (2004) 59(5):432–439.
   PubMed Web of Science ®Google Scholar
• SCOTT-TAYLOR TH, PETTENGELL R, CLARKE I et al.: Human tumour and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines. Biochim. Biophys. Acta (2000) 1500(3):265–279.
   PubMed Web of Science ®Google Scholar
• ORENTAS RJ, SCHAUER D, BIN Q, JOHNSON BD: Electrofusion of a wealdy immunogenic neuroblastoma with dendritic cells produces a tumor vaccine. Cell. ImmunoL (2001) 213(1):4–13.
   PubMed Web of Science ®Google Scholar
• HAYASHI T, TANAKA H, TANAKA J et al.: Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion. Clin. ImmunoL (2002) 104(1):14–20.
   PubMed Web of Science ®Google Scholar
• WEISE JB, HILPERT F, HEISER A et al.: Electrofusion generates diverse DC-tumour cell hybrids for cancer immunotherapy. Anticancer Res. (2004) 24(2B):929–934.
   Google Scholar
• TREVOR KT, COVER C, RUIZ YW et al.: Generation of dendritic cell-tumor cell hybrids by electrofusion for clinical vaccine application. Cancer ImmunoL Immunother. (2004) 53(8):705–714.
   PubMed Web of Science ®Google Scholar
• KJAERGAARD J, SHIMIZU K, SHU S: Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine. Cell. ImmunoL (2003) 225(2):65–74.
   PubMed Web of Science ®Google Scholar
• SIDERS WM, VERGILIS KI,, JOHNSON C, SHIELDS J, KAPLAN JM: Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells. MoL Ther. (2003) 7(4):498–505.
   PubMed Web of Science ®Google Scholar
• TANAKA H, SHIMIZU K, HAYASHI T, SHU S: Therapeutic immune response induced by electrofusion of dendritic and tumor cells. Cell. Immunol (2002) 220(1):1–12.
   PubMed Web of Science ®Google Scholar
• JANTSCHEFF P, SPAGNOLI G, ZAJAC P, ROCHLITZ CF: Cell fusion: an approach to generating constitutively proliferating human tumor antigen-presenting cells. Cancer Immunol Immunother. (2002) 51(7):367–375.
   PubMed Web of Science ®Google Scholar
• LINDNER M, SCHIRRMACHER V: Tumour cell-dendritic cell fusion for cancer immunotherapy: comparison of therapeutic efficiency of polyethylen-glycol versus electro-fusion protocols. Eur. j Clin. Invest. (2002) 32(3):207–217.
   PubMed Web of Science ®Google Scholar
• GOTTFRIED E, KRIEG R, EICHELBERG C, ANDREESEN R, MACKENSEN A, KRAUSE SW: Characterization of cells prepared by dendritic cell-tumor cell fusion. Cancer Immun. (2002) 2:15.
   PubMedGoogle Scholar
• NAKAMURA M, KIKUCHI T, KUFE DW, OHNO T: Antitumor effects of fusions composed of dendritic cells and fibroblasts transfected with genomic DNA from tumor cells. Cancer Immunol Immunother. (2004) 53(8):690–696.
   PubMed Web of Science ®Google Scholar
• GONG J, NIKRUI N, CHEN D et al: Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J. Immunol (2000) 165(3):1705–1711.
   PubMed Web of Science ®Google Scholar
• GONG J, AVIGAN D, CHEN D et al.: Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc. Natl. Acad. Sci. USA (2000) 97(6):2715–2718.
   PubMed Web of Science ®Google Scholar
• RAJE N, HIDESHIMA T, DAVIES FE et al.: Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Br. J. Haematol. (2004) 125(3):343–352.
   PubMed Web of Science ®Google Scholar
• BANAT GA, USLUOGLU N, HOECK M et al.: Dendritic cells fused with core binding factor-beta positive acute myeloid leukaemia blast cells induce activation of cytotoxic lymphocytes. Br. J. Haematol (2004) 126(4):593–601.
   PubMed Web of Science ®Google Scholar
• GONG J, KOIDO S, KATO Yet al: Induction of anti-leukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts. Leuk. Res. (2004) 28(12):1303–1312.
   PubMed Web of Science ®Google Scholar
• LUNDQVIST A, PALMBORG A, BIDLA Get al.: Allogeneic tumor-dendritic cell fusion vaccines for generation of broad prostate cancer T-cell responses. Med. Oncol (2004) 21(2):155–165.
   Google Scholar
• XU F, YE YJ, WANG S: In vitro antitumor immune response induced by fusion of dendritic cells and colon cancer cells. World J. Gastroenterol (2004) 10(8):1162–1166.
   PubMed Web of Science ®Google Scholar
• AVIGAN D, VASIR B, GONG J et al: Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin. Cancer Res. (2004) 10(14):4699–4708.
   PubMed Web of Science ®Google Scholar
• TREFZER U, HERBERTH G, WOHLAN K et al.: Vaccination with hybrids of tumor and dendritic cells induces tumor-specific T-cell and clinical responses in melanoma stage III and IV patients. Int. J. Cancer (2004) 110(5):730–740.
   PubMed Web of Science ®Google Scholar
• HAENSSLE HA, KRAUSE SW, EMMERT S et al.: Hybrid cell vaccination in metastatic melanoma: clinical and immunological results of a Phase I/II study. Immunother. (2004) 27(2):147–155.
   PubMed Web of Science ®Google Scholar
• KRAUSE SW, NEUMANN C, SORURI A et al.: The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells. Immunother. (2002) 25(5):421–428.
   PubMed Web of Science ®Google Scholar
• HOMMA S, MATAI K, IRIE M, OHNO T, KUFE D, TODA G: Immunotherapy using fusions of autologous dendritic cells and tumor cells showed effective clinical response in a patient with advanced gastric carcinoma. J. Gastroenterol (2003) 38(10):989–994.
   PubMed Web of Science ®Google Scholar
• KIKUCHI T, AKASAKI Y, IRIE M et al: Results of a Phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother. (2001) 50(7):337–344.
   PubMed Web of Science ®Google Scholar
• KIKUCHI T, AKASAKI Y, ABET et al.: Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. Immmunother. (2004) 27(6):452–459.
   PubMed Web of Science ®Google Scholar
• AVIGAN D, GEORGE DJ, KANTOFF PW et al.: Interim safety and efficacy results from a Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. ASCO Annual Meeting Proceedings. J. Clin. Oncol (2004) 22:169–176.
   Google Scholar
• BARBUTO JA, ENSINA LF, NEVES AR et al.: Dendritic cell-tumor cell hybrid vaccination for metastatic cancer. Cancer Immunol Immunother. (2004) 53(12):1111–1118.
   PubMed Web of Science ®Google Scholar
• BROWN RD, POPE B, MURRAY A et al: Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD4OLT stimulation because of inhibition by transforming growth factor-betal and interleukin-10. Blood (2001) 98(10):2992–2998.
   PubMed Web of Science ®Google Scholar
• AVIGAN D, WU Z, GONG J et al: Selective in vivo mobilization with granulocyte macrophage colony-stimulating factor (GM-CSF)/granulocyte-CSF as compared to G-CSF alone of dendritic cell progenitors from peripheral blood progenitor cells in patients with advanced breast cancer undergoing autologous transplantation. Clin. Cancer Res. (1999) 5(10):2735–2741.
   PubMed Web of Science ®Google Scholar
• TAKAGI Y, KIKUCHI T, NIIMURA M, OHNO T: Anti-tumor effects of dendritic and tumor cell fusions are not dependent on expression of MHC class I and II by dendritic cells. Cancer Lett. (2004) 213(1):49–55.
   PubMed Web of Science ®Google Scholar
• LI J, HOLMES LM, FRANEK KJ et al: Purified hybrid cells from dendritic cell and tumor cell fusions are superior activators of antitumor immunity. Cancer Immunol Immunother. (2001) 50(9):456–462.
   PubMed Web of Science ®Google Scholar
• TAKEDA A, HOMMA S, OKAMOTO T, KUFE D, OHNO T: Immature dendritic cell/tumor cell fusions induce potent antitumour immunity. Eur. j Clin. Invest. (2003) 33(10):897–904.
   PubMed Web of Science ®Google Scholar
• TANAKA Y, KOIDO S, CHEN D et al: Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice. Clin. Immunol (2001) 101(2):192–200.
   PubMed Web of Science ®Google Scholar
• SAUTER B, ALBERT ML, FRANCISCO L et al: Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med. (2000) 191(3):423–434.
   PubMed Web of Science ®Google Scholar
• CHEN Z, MOYANA T, SAXENA A et al: Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int. J. Cancer (2001) 93(4):539–548.
   PubMed Web of Science ®Google Scholar
• LIU Y, ZHANG W, CHANT, SAXENA A, XIANG J: Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity. Leuk. Res. (2002) 26(8):757–763.
   PubMed Web of Science ®Google Scholar
• DRANOFF G, JAFFEE E, LAZENBY A et al.: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. NatL Acad. Sci. USA (1993) 90(8):3539–3543.
   PubMed Web of Science ®Google Scholar
• SASAKI MG, FOCCACIA R, DE MESSIAS-REASON IJ: Efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant for hepatitis B virus in patients with HIV infection. Vaccine (2003) 21(30:4545–4549.
   PubMedGoogle Scholar
• ROSENBERG SA, DUDLEY ME: Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc. NatL Acad. Sci. USA (2004) 101\(Suppl. 2):14639–14645.
   Google Scholar
• TURK MJ, GUEVARA-PATINO JA, RIZZUTO GA, ENGELHORN ME, HOUGHTON AN: Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med. (2004) 200(6):771–782.
   PubMed Web of Science ®Google Scholar
• YOSHINO I, YANO T, MURATA M et al.: Tumor-reactive T-cells accumulate in lung cancer tissues but fail to respond due to tumor cell-derived factor. Cancer Res. (1992) 52(4):775–781.
   PubMed Web of Science ®Google Scholar
• WANG Q, STANLEY J, KUDOH S et al.: T cells infiltrating non-Hodgkin's B cell lymphomas show altered tyrosine phosphorylation pattern even though T cell receptor/CD3-associated kinases are present. J. Immunol. (1995) 155(3):1382–1392.
   PubMed Web of Science ®Google Scholar
• DWORACKI G, MEIDENBAUER N, KUSS I et al.: Decreased zeta chain expression and apoptosis in CD3+ peripheral blood T lymphocytes of patients with melanoma. Clin. Cancer Res. (2001) 7(3 Suppl.):947s–957s.
   Google Scholar
• TATSUMI T, KIERSTEAD LS, RANIERI E et al.: Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J. Exp. Med. (2002) 196(5):619–628.
   PubMed Web of Science ®Google Scholar
• UZZO RG, RAYMAN P, KOLENKO V et al.: Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. Clin. Cancer Res. (1999) 5(5):1219–1229.
   PubMed Web of Science ®Google Scholar
• YANG AS, LATTIME EC: Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. Cancer Res. (2003) 63(9):2150–2157.
   PubMed Web of Science ®Google Scholar
• MONTI P, LEONE BE, ZERBI A et ell.: Tumor-derived MUC1 mucins interact with differentiating monocytes and induce IL-10highIL-12low regulatory dendritic cell. Immunol. (2004) 172(12):7341–7349.
   Google Scholar
• GREGOR PD, WOLCHOK JD, FERRONE CR et al.: CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine (2004) 22(13-14):1700–1708.
   PubMed Web of Science ®Google Scholar
• HODI FS, MIHM MC, SOIFFER RJ et al.: Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Nail. Acad. Sci. USA (2003) 100(8):4712–4717.
   PubMed Web of Science ®Google Scholar
• TANAKA H, TANAKA J, KJAERGAARD J, SHU S: Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. Immunother. (2002) 25(3):207–217.
   PubMed Web of Science ®Google Scholar
• ASAVAROENGCHAI W, KOTERA Y, MULE JJ: Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc. Nail. Acad. Sci. USA (2002) 99(2):931–936.
   PubMed Web of Science ®Google Scholar
• BENDANDI M, GOCKE CD, KOBRIN CB et al.: Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med. (1999) 5(10):1171–1177.
   PubMed Web of Science ®Google Scholar
• CHEN D, XIA J, TANAKA Y et ell.: Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. Immunology (2003) 109(2):300–307.
   Google Scholar